Trials / Conditions / Advanced Renal Cell Carcinoma (aRCC)
Advanced Renal Cell Carcinoma (aRCC)
4 registered clinical trials studyying Advanced Renal Cell Carcinoma (aRCC) — 2 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advan NCT07188896 | Brian Rini | Phase 2 |
| Not Yet Recruiting | Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma NCT07159191 | Peking Union Medical College Hospital | Phase 2 |
| Completed | Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinom NCT06345183 | Bristol-Myers Squibb | — |
| Completed | Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination NCT04957160 | Ipsen | — |